|Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target|
L Peyrin-Biroulet, W Sandborn, BE Sands, W Reinisch, W Bemelman, ...
American Journal of Gastroenterology 110 (9), 1324-1338, 2015
|Recent trends in the epidemiology of inflammatory bowel diseases: up or down?|
World journal of gastroenterology: WJG 12 (38), 6102, 2006
|European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis|
EF Stange, SPL Travis, S Vermeire, W Reinisch, K Geboes, ...
Journal of Crohn's and Colitis 2 (1), 1-23, 2008
|The burden of inflammatory bowel disease in Europe|
J Burisch, T Jess, M Martinato, PL Lakatos, ECCO-EpiCom
Journal of Crohn's and Colitis 7 (4), 322-337, 2013
|Geographical variability and environmental risk factors in inflammatory bowel disease|
SC Ng, CN Bernstein, MH Vatn, PL Lakatos, EV Loftus, C Tysk, ...
Gut 62 (4), 630-649, 2013
|Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies|
PL Lakatos, L Lakatos
World journal of gastroenterology: WJG 14 (25), 3937, 2008
|East–West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort|
J Burisch, N Pedersen, S Čuković-Čavka, M Brinar, I Kaimakliotis, ...
Gut 63 (4), 588-597, 2014
|Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study|
L Lakatos, T Pandur, G David, Z Balogh, P Kuronya, A Tollas, PL Lakatos
World journal of gastroenterology 9 (10), 2300, 2003
|3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: surgical management and special situations|
P Gionchetti, A Dignass, S Danese, FJ Magro Dias, G Rogler, PL Lakatos, ...
Journal of Crohn's and Colitis 11 (2), 135-149, 2017
|Extraintestinal manifestations of inflammatory bowel disease|
SR Vavricka, A Schoepfer, M Scharl, PL Lakatos, A Navarini, G Rogler
Inflammatory bowel diseases 21 (8), 1982-1992, 2015
|The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease|
M Harbord, V Annese, SR Vavricka, M Allez, M Barreiro-de Acosta, ...
Journal of Crohn's and Colitis 10 (3), 239-254, 2016
|Risk factors for ulcerative colitis–associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study|
L Lakatos, G Mester, Z Erdelyi, G David, T Pandur, M Balogh, S Fischer, ...
Inflammatory bowel diseases 12 (3), 205-211, 2006
|Smoking in inflammatory bowel diseases: good, bad or ugly?|
PL Lakatos, T Szamosi, L Lakatos
World journal of gastroenterology: WJG 13 (46), 6134, 2007
|Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001|
L Lakatos, G Mester, Z Erdelyi, M Balogh, I Szipocs, G Kamaras, ...
World journal of gastroenterology 10 (3), 404, 2004
|Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between …|
PL Lakatos, PA Golovics, G David, T Pandur, Z Erdelyi, A Horvath, ...
American Journal of Gastroenterology 107 (4), 579-588, 2012
|Hospitalisations and surgery in Crohn's disease|
CN Bernstein, EV Loftus, SC Ng, PL Lakatos, B Moum
Gut 61 (4), 622-629, 2012
|Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn’s disease: phenotype-genotype correlations|
PL Lakatos, L Lakatos, F Szalay, C Willheim-Polli, C Österreicher, ...
World journal of gastroenterology: WJG 11 (10), 1489, 2005
|ECCO-EpiCom. The burden of inflammatory bowel disease in Europe|
J Burisch, T Jess, M Martinato, PL Lakatos
J Crohns Colitis 7 (4), 322-337, 2013
|Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002–2006|
L Lakatos, LS Kiss, G David, T Pandur, Z Erdelyi, G Mester, M Balogh, ...
Inflammatory bowel diseases 17 (12), 2558-2565, 2010
|Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort|
KB Gecse, BD Lovász, K Farkas, J Banai, L Bene, B Gasztonyi, ...
Journal of Crohn's and Colitis 10 (2), 133-140, 2016